Boston biotech growth faces rising Chinese competition

Massachusetts's biotechnology industry faces decline as the region lost over 1,100 biopharma jobs in 2024, with significant lab space sitting empty. China has targeted biotech as a strategic priority since 2015, increasing cross-border licensing deals and investments with Chinese firms, challenging U.S. dominance. A bipartisan bill, the Biotech Investment National Security Act, aims to prevent American investments from strengthening foreign adversaries’ biotech capabilities, emphasizing the need to protect U.S. leadership by investing in research, technology, and infrastructure.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article